Even though Saxenda had already been approved for obesity treatment, the use of GLP-1 receptor agonists for weight loss really picked up steam with Ozempic, perhaps because Saxenda was a daily injection, while Ozempic was a weekly injection. The gene discussed is GLP1R; the disease is obesity disorder.